-+ 0.00%
-+ 0.00%
-+ 0.00%

Satellos publishes investor presentation on SAT-3247 muscle regeneration approach for Duchenne dystrophy

PUBT·04/22/2026 23:04:45
Listen to the news
Satellos publishes investor presentation on SAT-3247 muscle regeneration approach for Duchenne dystrophy
  • Satellos outlined Phase 2 development for lead DMD candidate SAT-3247, positioning it as an oral daily tablet intended for patients regardless of genetic subtype.
  • Company targets 2026 readouts from two Phase 2 studies, including BASECAMP in ambulatory children ages 7-9 and TRAILHEAD in adults ages 16 and older.
  • Plan calls for accelerated approval filing in 2027 based on muscle regeneration evidence and functional measures.
  • Presentation highlighted Phase 1b grip strength gains of 118.6% in dominant hands and 97.9% in non-dominant hands.
  • Satellos cited preclinical data showing up to 4x strength gains in DMD canines over 4 months following SAT-3247 treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.